In this episode, we discuss two new anti-diabetic medications: empagliflozin (Jardiance) and the EMPA-REG OUTCOME trial as well as dulaglutide (Trulicity), a new GLP1 agonist.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
This website doesn't track the visitors or use any cookies. Made by Alex Barredo. Send your feedback to alex@barredo.es.
